NanoVision Diagnostics

MARKET ENTRY

NanoVision Diagnostics will offer its breakthrough technology as a diagnostic service to medical specialists including pathologists, oncologists, gastroenterologists and surgeons.

The initial focus of NanoVision Diagnostics is on breast and colon cancers.  The NanoVision Diagnostics system has been demonstrated as broadly applicable to many solid tumors including cancers of the esophagus, bile ducts, pancreas, bladder, cervix, breast and colon.

BREAST CANCER

Predicting the Progression of Pre-Cancerous Breast Lesions

Patients with Atypical Ductal Hyperplasia (ADH) are at an increased risk for developing breast cancer. Unfortunately, difficulty in identifying ADH by standard pathological methods makes it challenging to determine proper clinical management, resulting in a high false positive rate and unnecessary follow-up surgeries.

NanoVision Diagnostics can reduce this false positive rate and predict the time-dependent risk of progression to breast cancer.

A retrospective clinical study on ADH patients demonstrates patients with positive NanoVision Diagnostics optical biomarkers have significantly higher risk of progression to cancer than patients with negative optical biomarkers. This study demonstrates the NanoVision Diagnostics test can guide the use of chemo-preventative therapies for these patients and reduce unnecessary surgeries. Click here for more information.

COLON CANCER

Using Rectal Biopsy to Detect Cancer Throughout the Colon

Inflammatory Bowel Disease (IBD) patients have elevated risk of colon cancer. Annual colonoscopy screening (visual examination combined with 64 biopsy samples of the entire colon) is indicated to assess the presence of cancer or precancerous dysplasia. This annual screening is expensive, inconvenient and carries risk of colon injury.

The NanoVision Diagnostics test was conducted on a single rectal biopsy from each patient and compared to the corresponding standard protocol colonoscopy. The NanoVision Diagnostics system was able to differentiate normal tissue from high-risk lesions (cancer or dysplasia) with nearly the accuracy of the standard protocol. This study demonstrates that the NanoVision Diagnostics test can diagnose cancer throughout an organ system, not just at the biopsy site, thus improving diagnostic accuracy.

The NanoVision Diagnostics can provide significant benefits compared to standard protocol colonoscopy. Multiple-biopsy colonoscopies cost thousands of dollars while the NanoVision Diagnostics test can be performed on a single rectal biopsy obtained in one office visit, creating substantial cost savings. Additionally, the NanoVision Diagnostics test avoids the risks and inconvenience of a colonoscopy. Click here for more information.